Cargando…
Intact FGF23 predicts serum phosphate improvement after combined nicotinamide and phosphate binder treatment in hemodialysis patients
BACKGROUND: Hyperphosphatemia is associated with increased mortality and cardiovascular morbidity of end-stage kidney failure (ESKF) patients. Managing serum phosphate in ESKF patients is challenging and mostly based on limiting intestinal phosphate absorption with low phosphate diets and phosphate...
Autores principales: | Egli-Spichtig, Daniela, Hamid, Ahmad Kamal, Arroyo, Eva Maria Pastor, Ketteler, Markus, Wiecek, Andrzej, Rosenkranz, Alexander R, Pasch, Andreas, Lorenz, Horst, Hellmann, Burkhard, Karus, Michael, Ammer, Richard, Rubio-Aliaga, Isabel, Wagner, Carsten A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539220/ https://www.ncbi.nlm.nih.gov/pubmed/37779856 http://dx.doi.org/10.1093/ckj/sfad040 |
Ejemplares similares
-
Efficacy and Safety of a Novel Nicotinamide Modified-Release Formulation in the Treatment of Refractory Hyperphosphatemia in Patients Receiving Hemodialysis—A Randomized Clinical Trial
por: Ketteler, Markus, et al.
Publicado: (2020) -
Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial
por: Ketteler, Markus, et al.
Publicado: (2022) -
Renal Dnase1 expression is regulated by FGF23 but loss of Dnase1 does not alter renal phosphate handling
por: Egli-Spichtig, Daniela, et al.
Publicado: (2021) -
Inflammation: a putative link between phosphate metabolism and cardiovascular disease
por: Voelkl, Jakob, et al.
Publicado: (2021) -
Iron-based phosphate binders: do they offer advantages over currently available phosphate binders?
por: Negri, Armando Luis, et al.
Publicado: (2015)